GSK charitable support valued at £282 million in 2007

GlaxoSmithKlineGlaxoSmithKline reported its 2007 global giving to charitable initiatives totalled £282 million, equivalent to almost 4% of pre-tax profits for the company (with the FTSE 100 average around 1%). Donations of albendazole treatments for the company's flagship programme to eliminate Lymphatic Filariasis (commonly known as elephantiasis) were valued at £14 million, bringing the total number of treatments given since GSK made its commitment 10 years ago to almost 750 million.

Commenting on the figures JP Garnier, CEO of GlaxoSmithKline said: "I want GSK to be part of global healthcare solutions, not only through our medicines and vaccines, but also through our public health programs and work with communities. This is embedded in our business, not just an 'add on'; whether it is eliminating LF, supporting HIV communities, fighting malaria, or preventing diabetes. Our partnerships offer more than a helping hand; they are transforming the lives and prospects of people all over the world."

GSK supports health and education programmes in more than 100 countries through donations of medicines and through long-term partnerships that provide financial and practical support.The £282 million investment includes product donations valued at £224 million, cash giving of £41 million and other in-kind donations, such as equipment, valued at £3 million. The costs to administer and deliver these programmes were £14 million.

The £224 million of product donations included:

  • A continuation of the Lymphatic Filariasis elimination programme which since 1998 has seen the donation of almost 750 million albendazole treatments by GSK. This programme, now in the tenth year of GSK's involvement working with the World Health Organization and other partners aims to eliminate LF by 2020.
  • £15 million of humanitarian product donations for the most impoverished communities and international relief efforts, including the cyclone in Bangladesh and floods in Mexico. GSK provides significant quantities of essential quality medicines through a proven crisis response process.
  • £194 million provided via Patient Assistance Programs (PAP) for low income patients in the USA. GSK provides $1 million in medicines per day to patients who cannot afford to pay for their prescriptions. These include products that are able to be used in an outpatient setting across all therapeutic areas, such as: respiratory, psychiatric, neurology, metabolic, CV.

Cash donations of £41 million delivered through partnerships with hundreds of charitable organisations.

Over £20 million was directed to global and local health programmes. With GSK funding the Malaria Consortium is delivering 'Mobilising for Malaria', a programme to increase awareness and mobilise resources for this killer disease. In its 15th year, GSK's Positive Action for HIV and AIDS delivered effective education, prevention and health care services in 19 countries. GSK's PHASE (Personal Hygiene And Sanitation Education) programme continues to grow now reaching half a million school children in 12 countries, helping to prevent diarrhoeal diseases through better hand-washing.

Donations of over £11 million supported education programmes, including science education and literacy. Through Crest Star Investigators school children will have access to engaging science activities at their UK after-school clubs. The target is to reach 5,000 schools and 55,000 children by 2010. GSK's 'Science in the Summer' enables 6000 children in Philadelphia to participate in hands-on experiments in libraries. GSK continues to support the Institute for a Competitive Workforce, a business coalition staffed by the Business Civic Leadership Center of the US Chamber of Commerce. This is aimed at improving education and creating a skilled workforce for the future.

In addition to the company donations GlaxoSmithKline employees contributed more than £3.5 million to charities in the UK and US through employee-organised giving programmes. Many also gave their time and skills to their local communities. Further details of GSK's giving and activities relating to other corporate responsibility areas are published today in GSK Corporate Responsibility report on www.gsk.com.

Most Popular Now

Pfizer's elranatamab granted FDA Breakthrough Ther…

Pfizer Inc. (NYSE:PFE) announced its investigational cancer immunotherapy, elranatamab, received Breakthrough Therapy Designation from the U.S. Food and Drug Administrati...

Vividion Therapeutics names Jenna Goldberg as Chie…

Vividion Therapeutics, Inc., a biopharmaceutical company utilizing novel discovery technologies to unlock high value, traditionally undruggable targets with precision the...

Pfizer and BioNTech receive positive CHMP opinion …

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced a booster dose of their Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine (COMIRNATY® Original/Omicron ...

Bayer with continued strong performance

The Bayer Group maintained its strong business performance across all three divisions in the third quarter. "Despite rising inflation and global supply chain problems, we...

Sanofi and GSK's next-generation COVID-19 booster …

After the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for VidPrevtyn® Beta, the vaccine was approved by t...

Sugar molecules as a target in cancer therapy

Cancer cells use sugar molecules on their surface to disable attacks by the body's immune system. Researchers at the University of Basel now report on how this mechanism ...

COVID vaccination improves effectiveness of cancer…

Patients with nasopharyngeal cancer are often treated with drugs that activate their immune system against the tumor. Until now, it was feared that vaccination against Co...

GSK announces positive Phase IIa study results for…

GSK plc (LSE/NYSE: GSK) announced positive results from a Phase IIa study demonstrating that GSK3036656, a first-in-class investigational antitubercular agent, was well t...

Making melanoma immortal: Pitt scientists discover…

Scientists at the University of Pittsburgh School of Medicine have discovered the missing puzzle piece in the mystery of how melanoma tumors control their mortality. I...

New drug shows promise for fighting both COVID-19 …

While vaccination can provide life-saving protection against COVID-19, scientists are still searching for ways to treat severe infections, including in people who cannot ...

Machine learning can help predict patient response…

Predicting which patients will respond well to treatment is a quandary that has plagued the field of cancer immunotherapy for more than four decades. Now, researchers at ...

Study reveals vaccine confidence declined consider…

A new study suggests that, despite the success of the COVID-19 vaccination campaigns, vaccine confidence has declined significantly since the start of the pandemic. Re...